Rufinamide was evaluated in vitro to determine which enzyme(s) are responsible for rufinamide hydrolysis and whether valproate, one of its metabolites (valproyl-CoA), and/or the rufinamide hydrolysis product (CGP 47292) could inhibit hydrolysis. Rufinamide hydrolysis was mediated primarily by human carboxylesterase (hCE) 1 and was nonsaturable up to 500 μM. Two-thirds of rufinamide hydrolysis was estimated to occur in human microsomes and one-third in cytosol. Valproate was a selective inhibitor for hCE1 compared to hCE2 and inhibition had a greater impact on rufinamide hydrolysis in microsomes than in cytosol. Valproyl-CoA caused similar inhibition of rufinamide hydrolysis in both microsomes and cytosol. Carboxylesterases were not significantly inhibited by CGP 47292. Inhibition of in vitro rufinamide hydrolysis by valproate could offer an explanation for the observed in vivo drug-drug interaction between the two antiepileptic drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/187231211798472511 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carboxylesterase 1-Based Drug-Drug Interaction Potential of Remimazolam: Studies and Literature Review.
Curr Drug Metab
November 2024
Department of R & D, Paion Germany GmbH, Aachen, Germany.
Background: The ultra-short-acting benzodiazepine remimazolam, approved for procedural sedation and general anesthesia, is inactivated by carboxylesterase 1 (CES1).
Objective: Remimazolam´s involvement in CES1-mediated drug-drug interactions (DDIs) was investigated.
Methods: Possible interactions of remimazolam were studied in co-exposure experiments with eleven different drugs.
HPLC-PDA identification and resolution of rufinamide forced degradation impurities: A congregated chemometric expedite optimization coupled with factorials and desirability.
Biomed Chromatogr
May 2022
Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, MS, India.
Rufinamide is used presently to treat Lenaux-Gastaut syndrome. A full factorial design and desirability approach was investigated for the optimization of hydrolytic stress via response surface curves (RSCs). The degradation impurities were identified and resolved using reversed-phase high-performance liquid chromatography (RP-HPLC) on the Qualisil® BDS C column.
View Article and Find Full Text PDFDevelopment of a validated stability-indicating HPTLC method for rufinamide in bulk and its pharmaceutical dosage form.
J Chromatogr Sci
July 2015
Faculty of Pharmacy, Dharamsinh Desai University, Nadiad, Gujarat.
A sensitive, selective, precise and stability indicating a high-performance thin layer chromatographic method for the analysis of rufinamide (Rf) in bulk drug and its formulations was developed and validated. The method employed thin layer chromatography aluminum plates precoated with silica gel 60 F254 as the stationary phase. The solvent system consisted of chloroform : methanol : glacial acetic acid (9 : 1 : 0.
View Article and Find Full Text PDFInvestigation of the metabolism of rufinamide and its interaction with valproate.
Drug Metab Lett
December 2011
Eisai Inc., Andover, Massachusetts 01810, USA.
Rufinamide was evaluated in vitro to determine which enzyme(s) are responsible for rufinamide hydrolysis and whether valproate, one of its metabolites (valproyl-CoA), and/or the rufinamide hydrolysis product (CGP 47292) could inhibit hydrolysis. Rufinamide hydrolysis was mediated primarily by human carboxylesterase (hCE) 1 and was nonsaturable up to 500 μM. Two-thirds of rufinamide hydrolysis was estimated to occur in human microsomes and one-third in cytosol.
View Article and Find Full Text PDFRufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Epilepsia
July 2008
Institute of Neurology IRCCS C. Mondino Foundation and Clinical Pharmacology Unit, University of Pavia, Pavia, Italy.
Rufinamide is a new, orally active antiepileptic drug (AED), which has been found to be effective in the treatment of partial seizures and drop attacks associated with the Lennox-Gastaut syndrome. When taken with food, rufinamide is relatively well absorbed in the lower dose range, with approximately dose-proportional plasma concentrations up to 1,600 mg/day, but less than dose-proportional plasma concentrations at higher doses due to reduced oral bioavailability. Rufinamide is not extensively bound to plasma proteins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!